<DOC>
	<DOCNO>NCT02711137</DOCNO>
	<brief_summary>This open-label , dose-escalation/dose-expansion study INCB057643 subject advance malignancy . Part 1 determine maximum tolerate dose INCB057643 and/or tolerate dose demonstrates sufficient pharmacologic activity . Part 2 evaluate safety , preliminary efficacy , PK , PD dose ( ) select Part 1 select tumor type .</brief_summary>
	<brief_title>A Phase 1/2 , Open-Label Safety Tolerability Study INCB057643 Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm diagnosis advanced malignancy : Part 1 : advanced solid tumor hematologic malignancy Part 2 : histologically confirm disease specific tumor type Progressed follow least 1 line prior therapy establish therapy know provide clinical benefit ( include subject intolerant establish therapy ) Life expectancy &gt; 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status Part 1 : 0 1 Part 2 : 0 , 1 , 2 Willingness avoid pregnancy father child Inadequate bone marrow function per protocolspecified hemoglobin , platelet count , absolute neutrophil count Inadequate organ function per protocolspecified total bilirubin , AST ALT , creatinine clearance Receipt anticancer medication investigational drug within protocolspecified interval Unless approve medical monitor , may receive allogeneic hematopoietic stem cell transplant within 6 month treatment , active graftversushostdisease follow allogeneic transplant Unless approve medical monitor , may receive autologous hematopoietic stem cell transplant within 3 month treatment Any unresolved toxicity â‰¥ Grade 2 ( except stable Grade 2 peripheral neuropathy alopecia ) previous anticancer therapy Radiotherapy within 2 week initiation treatment . Palliative radiation treatment nonindex bone lesion perform less 2 week treatment initiation may consider medical monitor approval Currently active uncontrolled infectious disease require systemic antibiotic , antifungal , antiviral treatment Untreated brain central nervous system ( CNS ) metastases brain/CNS metastasis progress History presence abnormal electrocardiogram ( ECG ) , investigator 's opinion , clinically meaningful</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>myeloproliferative neoplasm ( MPN )</keyword>
	<keyword>MDS/MPN</keyword>
	<keyword>myelofibrosis ( MF )</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>glioblastoma multiforme ( GBM )</keyword>
	<keyword>NUT midline carcinoma</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>diffuse large B-cell lymphoma ( DLBCL )</keyword>
	<keyword>double-hit</keyword>
	<keyword>triple-hit</keyword>
	<keyword>myc</keyword>
	<keyword>bromodomain extra-terminal ( BET ) inhibitor</keyword>
</DOC>